Cargando…
Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)—study protocol for a multicentre, randomized phase III trial
BACKGROUND: Hypofractionated radiotherapy is the current standard for adjuvant radiotherapy across many centres. Further hypofractionation may be possible but remains to be investigated in non-Caucasian populations with more advanced disease, with a higher proportion of patients requiring mastectomy...
Autores principales: | Chatterjee, Sanjoy, Chakraborty, Santam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526182/ https://www.ncbi.nlm.nih.gov/pubmed/32998747 http://dx.doi.org/10.1186/s13063-020-04751-y |
Ejemplares similares
-
Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma
por: Park, Jongmoo, et al.
Publicado: (2018) -
Adjuvant radiation therapy in breast cancer: Recent advances & Indian data
por: Chakraborty, Santam, et al.
Publicado: (2021) -
1-week hypofractionated adjuvant whole-breast radiotherapy: towards a new standard?
por: Levy, Antonin, et al.
Publicado: (2020) -
Synchronous bilateral breast cancer treated with a 3-week hypofractionated radiotherapy schedule: clinical and dosimetric outcomes
por: Gadea, J., et al.
Publicado: (2021) -
Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?
por: Shibamoto, Yuta, et al.
Publicado: (2016)